ABT450r-ABT267-ABT333 +/- Ribavirin — Competitive Intelligence Brief

ABT450r-ABT267-ABT333 +/- Ribavirin (ABT450r-ABT267-ABT333 +/- Ribavirin) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Direct-acting antiviral (DAA) combination. Area: Infectious Disease / Virology.

marketed Direct-acting antiviral (DAA) combination HCV NS3/4A protease, NS5A protein, NS5B polymerase Infectious Disease / Virology Small molecule

Target snapshot

ABT450r-ABT267-ABT333 +/- Ribavirin (ABT450r-ABT267-ABT333 +/- Ribavirin) — Ottawa Hospital Research Institute. This is a fixed-dose combination of three direct-acting antivirals that inhibit hepatitis C virus (HCV) NS3/4A protease, NS5A protein, and NS5B polymerase, with optional ribavirin co-administration.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
ABT450r-ABT267-ABT333 +/- Ribavirin TARGET	ABT450r-ABT267-ABT333 +/- Ribavirin	Ottawa Hospital Research Institute	marketed	Direct-acting antiviral (DAA) combination	HCV NS3/4A protease, NS5A protein, NS5B polymerase
paritaprevir/ritonavir/ombitasvir + dasabuvir +/- ribavirin	paritaprevir/ritonavir/ombitasvir + dasabuvir +/- ribavirin	American Research Corporation	marketed	HCV protease inhibitor / NS5A inhibitor / polymerase inhibitor combination	HCV NS3/4A protease, NS5A protein, NS5B polymerase
Daclinza and Sunvepra	Daclinza and Sunvepra	Pusan National University Hospital	marketed	Direct-acting antiviral (DAA) combination	HCV NS5A protein and HCV NS5B RNA-dependent RNA polymerase
Post-transplant Grazoprevir and Elbasvir	Post-transplant Grazoprevir and Elbasvir	University of Maryland, Baltimore	marketed	Direct-acting antiviral (DAA) combination	HCV NS3/4A protease and NS5A protein
Sofosbuvir, Ribavirin, and Stribild	Sofosbuvir, Ribavirin, and Stribild	Saint Michael's Medical Center	marketed	Direct-acting antiviral (DAA) combination; antiretroviral combination	HCV NS5B RNA polymerase; HIV integrase; HIV reverse transcriptase
Sofosbuvir and Velpatasvir	Sofosbuvir and Velpatasvir	Hannover Medical School	marketed	Direct-acting antiviral (DAA) combination	HCV NS5B polymerase and NS5A protein
Glecaprevir / Pibrentasvir Oral Tablet [Mavyret]	Glecaprevir / Pibrentasvir Oral Tablet [Mavyret]	Massachusetts General Hospital	marketed	Direct-acting antiviral (DAA) combination	HCV NS3/4A protease and NS5A protein

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Direct-acting antiviral (DAA) combination class)

1. Massachusetts General Hospital · 3 drugs in this class
2. Egyptian Liver Hospital · 3 drugs in this class
3. Hannover Medical School · 2 drugs in this class
4. University of Maryland, Baltimore · 2 drugs in this class
5. Iran Hepatitis Network · 2 drugs in this class
6. Partners in Health · 2 drugs in this class
7. HaEmek Medical Center, Israel · 1 drug in this class
8. Almaza Military Fever Hospital · 1 drug in this class
9. Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba · 1 drug in this class
10. Federal University of São Paulo · 1 drug in this class